Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.
about
Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of actionMultiple indications for everolimus after liver transplantation in current clinical practice.Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.Review on immunosuppression in liver transplantation.Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1AISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma.Surgical strategy for liver cancers in the era of effective chemotherapy.Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasisLet-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression.Mammalian target of rapamycin inhibition in hepatocellular carcinoma.Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.Effects of Ras homolog gene family, member C gene silencing combined with rapamycin on hepatocellular carcinoma cell growth.Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma.Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP.Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitorsmiR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2
P2860
Q27693179-B716F074-4FA0-4AF6-BB8F-260E7005D5C7Q33891730-6FC11206-F001-4DA5-960C-4B3AF9163037Q35248527-0D9DFD1F-D580-4374-B90E-DD8DFD8857CAQ35668757-8E1DC6D1-38D9-4C0A-9AED-1F7CB434314CQ36356171-8AFE8E52-48B5-49DE-B190-7F6B3EA75F71Q36411445-7719A875-F06B-458F-8A4B-5E62559CD045Q37105519-53157E27-7241-4397-93CE-38B211819FCDQ37372436-2B7EE0D2-5AE1-4DA1-BF83-9E92D6A89372Q37454420-138F3B93-C6CE-4BA5-9456-2244263F0447Q37469797-C874285C-C8C9-49EC-ACA9-7383DE48A2F6Q38271964-1562DE1A-E6FE-4A87-A6EE-2F2EF953F156Q38312035-655D193D-4221-4938-A412-0F69F44CEF75Q38519928-28D7DBBC-39C2-4968-B357-6422540ABAD0Q38854124-CD58F34F-2094-401E-A6A0-9F28E4077959Q38958526-82FDF0BB-4354-4996-9CC8-13DCBA140618Q40859380-83FD839C-1F3A-4296-896F-430C5308C169Q47134775-C44C63B7-D590-4A47-B33C-B497FE82CD7AQ56335977-DDD1159B-3E18-496C-99A8-8EB168AB2C13Q57056187-0C5B2C25-55F4-4627-8EB8-4CDD307B9DC1
P2860
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Current and Future Treatment S ...... noma: Role of mTOR Inhibition.
@en
type
label
Current and Future Treatment S ...... noma: Role of mTOR Inhibition.
@en
prefLabel
Current and Future Treatment S ...... noma: Role of mTOR Inhibition.
@en
P2860
P356
P1433
P1476
Current and Future Treatment S ...... noma: Role of mTOR Inhibition.
@en
P2093
Richard S Finn
P2860
P304
P356
10.1159/000343839
P577
2012-11-01T00:00:00Z